Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. 1993

A J Hutchison, and R W Whitehouse, and H F Boulton, and J E Adams, and E B Mawer, and T J Freemont, and R Gokal
Renal Dialysis Unit, Manchester Royal Infirmary, United Kingdom.

We analyzed transiliac bone biopsy specimens from 30 end-stage renal failure patients, taken at the time of admission for CAPD training. Results were compared with values of iPTH, bone alkaline phosphatase, 1,25-dihydroxyvitamin D3, skeletal survey, quantitative computed tomography (QCT) and single photon absorptiometry (SPA) bone density measurements. Osteitis fibrosa was the most common histological diagnosis, present in 15 of the 30 patients (50%), with eight classified as "severe" and seven as "mild." Eight patients (27%) had adynamic bone lesion, four mixed renal osteodystrophy (13%), and two (7%) osteomalacia. The mean age of the adynamic group was higher than the osteitis fibrosa group (41 +/- 12.1 vs. 56 +/- 10.2 years; P < 0.01), and than the mixed group (39 +/- 7.5 vs. 56 +/- 10.2 years; P < 0.02). Levels of iPTH enabled discrimination between groups, but not between individual patients, and values correlated with bone alkaline phosphatase (r = 0.62; P < 0.001). Erosion of the terminal phalanges was seen on the plain X-rays of 7 of 15 patients with mild or severe OF, and in three patients with another diagnosis. The majority of patients (> 90%) had bone density measurements within the normal range. No significant correlation existed between QCT or SPA scores and any of the histomorphometric parameters, or iPTH. We conclude that iPTH is the most helpful non-invasive investigation in this group of patients. Plain X-ray of the hands is the most useful radiological investigation, but single measurements of bone density are not diagnostic.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010018 Osteomalacia Disorder caused by an interruption of the mineralization of organic bone matrix leading to bone softening, bone pain, and weakness. It is the adult form of rickets resulting from disruption of VITAMIN D; PHOSPHORUS; or CALCIUM homeostasis. Adult Rickets,Rickets, Adult
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D001842 Bone and Bones A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principal cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX. Bone Tissue,Bone and Bone,Bone,Bones,Bones and Bone,Bones and Bone Tissue,Bony Apophyses,Bony Apophysis,Condyle,Apophyses, Bony,Apophysis, Bony,Bone Tissues,Condyles,Tissue, Bone,Tissues, Bone
D002762 Cholecalciferol Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24. Vitamin D 3,(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol,Calciol,Cholecalciferols,Vitamin D3
D005260 Female Females
D005357 Fibrous Dysplasia of Bone A disease of bone marked by thinning of the cortex by fibrous tissue containing bony spicules, producing pain, disability, and gradually increasing deformity. Only one bone may be involved (FIBROUS DYSPLASIA, MONOSTOTIC) or several (FIBROUS DYSPLASIA, POLYOSTOTIC). Osteitis Fibrosa Disseminata,Fibrocartilaginous Dysplasia of Bone,Fibrocystic Dysplasia of Bone,Jaffe-Lichtenstein Disease,Bone Fibrocartilaginous Dysplasia,Bone Fibrocartilaginous Dysplasias,Bone Fibrocystic Dysplasia,Bone Fibrocystic Dysplasias,Bone Fibrous Dysplasia,Bone Fibrous Dysplasias,Jaffe Lichtenstein Disease

Related Publications

A J Hutchison, and R W Whitehouse, and H F Boulton, and J E Adams, and E B Mawer, and T J Freemont, and R Gokal
January 2018, Indian journal of endocrinology and metabolism,
A J Hutchison, and R W Whitehouse, and H F Boulton, and J E Adams, and E B Mawer, and T J Freemont, and R Gokal
January 2005, Seminars in dialysis,
A J Hutchison, and R W Whitehouse, and H F Boulton, and J E Adams, and E B Mawer, and T J Freemont, and R Gokal
September 2004, Clinical nephrology,
A J Hutchison, and R W Whitehouse, and H F Boulton, and J E Adams, and E B Mawer, and T J Freemont, and R Gokal
January 2011, Seminars in dialysis,
A J Hutchison, and R W Whitehouse, and H F Boulton, and J E Adams, and E B Mawer, and T J Freemont, and R Gokal
January 1980, Progress in biochemical pharmacology,
A J Hutchison, and R W Whitehouse, and H F Boulton, and J E Adams, and E B Mawer, and T J Freemont, and R Gokal
January 2003, Blood purification,
A J Hutchison, and R W Whitehouse, and H F Boulton, and J E Adams, and E B Mawer, and T J Freemont, and R Gokal
February 1980, Otolaryngologic clinics of North America,
A J Hutchison, and R W Whitehouse, and H F Boulton, and J E Adams, and E B Mawer, and T J Freemont, and R Gokal
February 1999, The Journal of clinical investigation,
A J Hutchison, and R W Whitehouse, and H F Boulton, and J E Adams, and E B Mawer, and T J Freemont, and R Gokal
January 1986, Advances in experimental medicine and biology,
A J Hutchison, and R W Whitehouse, and H F Boulton, and J E Adams, and E B Mawer, and T J Freemont, and R Gokal
January 1983, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association,
Copied contents to your clipboard!